Diabetes mellitus and cancer – UPDATE
Authors:
Račická E.
Authors‘ workplace:
MU Dr. RAČICKÁ, s. r. o., Diabetologická a interní ambulance, Ostrava
Published in:
Kardiol Rev Int Med 2019, 21(1): 19-23
Overview
Epidemiologic evidence suggests that cancer incidence is associated with diabetes mellitus. Diabetes is associated with an increased risk of cancer of the liver, pancreas, endometrium, colon/rectum, breast and bladder. The association may result from the shared factors between type 2 diabetes mellitus and tumours: older age, physical inactivity, obesity. The article also describes the association between colorectal neoplasia and metabolic syndrome. Colorectal cancer represents one of the greatest issues in contemporary healthcare. Czech Republic is among countries with the highest incidence of colorectal carcinoma. It also presents the preliminary results of a Czech multi-centre prospective study investigating colorectal carcinoma in diabetic and cardiovascular patients. Pancreatic cancer is another medicinal problem; its early diagnosis may contribute to a better prognosis of the patient. Diabetes mellitus caused by pancreatic cancer is a secondary diabetes called diabetes mellitus T3c. A multi-disciplinary preventive programme could help in the diagnostics of pancreatic cancer.
Keywords:
diabetes mellitus – cancer – colorectal neoplasia – sporadic pancreatic cancer
Sources
1. Národní onkologický registr. Ústav zdravotnických informací. Dostupné na: http:/ / www.uzis.cz/ registry-nzis/ nor.
2. American Diabetes Association. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes 2019. Diabetes Care 2019; 42 (Suppl 1): S34– S45. doi: 10.2337/ dc19-S004.
3. Suh S, Kim KW. Diabetes and cancer: is diabetes causally related to cancer? Diabetes Metab J 2011; 35(3): 193– 198. doi: 10.4093/ dmj.2011.35.3.193.
4. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92(18): 1472– 1489.
5. Irwin ML, Duggan C, Wang CY et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol 2011; 29(1): 47– 53. doi: 10.1200/ JCO.2010.28.4752.
6. Harrington SC, Weroha SJ, Reynolds C et al. Quantifying insulin receptor isoform expression in FPE breast tumors. Growth Horm IGF Res 2012; 22(3– 4): 108– 115. doi: 10.1016/ j.ghir.2012.04.001.
7. Malempati S, Weigel B, Ingle AM et al. Phase I/ II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012; 30(3): 256– 262. doi: 10.1200/ JCO.2011.37.4355.
8. Li D. Diabetes and pancreatic cancer. Mol Carcinog 2012; 51(1): 64– 74. doi: 10.1002/ mc.20771.
9. Herrera BM, Keildson S, Lindgren CM. Genetics and epigenetics of obesity. Maturitas 2011; 69(1): 41– 49. doi: 10.1016/ j.maturitas.2011.02.018.
10. Ye J, Jia J, Dong S et al. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev 2014; 23(3): 158– 165. doi: 10.1097/ CEJ.0b013e328364f293.
11. Remely M, Aumueller E, Jahn D et al. Microbiota and epigenetic regulation of inflammatory mediators in type 2 diabetes and obesity. Benef Microbes 2014; 5(1): 33– 43. doi: 10.3920/ BM2013.006.
12. Giri B, Dey S, Das T et al. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity. Biomed Pharmacother 2018; 107: 306– 328. doi: 10.1016/ j.biopha.2018.07.157.
13. Stefansdottir G, Zoungas S, Chalmers J et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia 2011; 54(7): 1608– 1614. doi: 10.1007/ s00125-011-2104-x.
14. Chang YL, Sheu WH, Lin SY et al. Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus. Clin Exp Med 2018; 18(3): 383– 390. doi: 10.1007/ s10238-018-0497-2.
15. Melvin JC, Holmberg L, Rohrmann S et al. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol 2013; 2013: 823849. doi: 10.1155/ 2013/ 823849.
16. Moysich KB, Freudenheim JL, Baker JA et al. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol Carcinog 2000; 27(1): 2– 9.
17. Yu O, Eberg M, Benayoun S et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 2014; 32(1): 5– 11. doi: 10.1200/ JCO.2013.49.4757.
18. Zhao Z, Cao X, Pan Y et al. Simvastatin downregulates HER2 via upregulation of PEA3 to induce cell death in HER2-positive breast cancer cells. Oncol Res 2012; 20(5– 6): 187– 195.
19. Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 2012; 135(1): 261– 269. doi: 10.1007/ s10549-012-2154-x.
20. Gagnière J, Raisch J, Veziant J et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 2016; 22(2): 501– 518. doi: 10.3748/ wjg.v22.i2.501.
21. Ahn J, Sinha R, Pei Z et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013; 105(24): 1907– 1911. doi: 10.1093/ jnci/ djt300.
22. Zavoral M, Vojtěchová G, Májek O et al. Populační screening kolorektálního karcinomu v České republice. Čas Lek Čes 2016; 155(1): 7– 12.
23. Cífková R, Škodová Z, Bruthans J et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/ 8. Czech MONICA and Czech post-MONICA. Atherosclerosis 2010; 211(2): 676– 681. doi: 10.1016/ j.atherosclerosis.2010.04.007.
24. Guize L, Pannier B, Thomas F et al. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis 2008; 101(9): 577– 583. doi: 10.1016/ j.acvd.2008.06.011.
25. Ozasa K, Ito Y, Suzuki K et al. Glucose intolerance and colorectal cancer risk in a nested case-control study among Japanese people. J Epidemiol 2005; 15 (Suppl 2): S180– S184. doi: 10.2188/ jea.15.S180.
26. Peeters PJ, Bazelier MT, Leufkens HG et al. The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity. Diabetes Care 2015; 38(3): 495– 502. doi: 10.2337/ dc14-1175.
27. Yuhara H, Steinmaus C, Cohen SE et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol 2011; 106(11): 1911– 1921; quiz 1922. doi: 10.1038/ ajg.2011.301.
28. Esposito K, Chiodini P, Capuano A et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 2013; 44(3): 634– 647. doi: 10.1007/ s12020-013-9939-5.
29. Suchanek S, Grega T, Ngo O et al. How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia? World J Gastroenterol 2016; 22(36): 8103– 8111. doi: 10.3748/ wjg.v22.i36.8103.
30. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011; 47(13): 1928– 1937. doi: 10.1016/ j.ejca.2011.03.003.
31. Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer 2012; 19(5): F9– F26. doi: 10.1530/ ERC-12-0105.
32. Frič P, Šedo A, Škrha J et al. Časná detekce sporadickeho karcinomu pankreatu. Čas Lek Čes 2016; 155(1): 44– 47.
33. Song S, Wang B, Zhang X et al. Long-term diabetes mellitus is associated with an increased risk of pancreatic cancer: a meta-analysis. PLoS One 2015; 10(7): e0134321. doi: 10.1371/ journal.pone.0134321.
34. Batabyal P, Vander Hoorn S, Christophi C et al. Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. Ann Surg Oncol 2014; 21(7): 2453– 2462. doi: 10.1245/ s10434-014-3625-6.
35. Chari ST, Leibson CL, Rabe KG et al. Pancreatic cancer associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134(1): 95– 101. doi: 10.1053/ j.gastro.2007.10.040.
36. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011; 47(13): 1928– 1937. doi: 10.1016/ j.ejca.2011.03.003.
37. Sah RP, Nagpal SJ, Mukhopadhyay D et al. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013; 10(7): 423– 433. doi: 10.1038/ nrgastro.2013.49.
38. Hart PA, Kamada P, Rabe KG et al. Weight loss precedes cancer specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas 2011; 40(5): 768– 772. doi: 10.1097/ MPA.0b013e318220816a.
39. Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology 2011; 11(3): 279– 294. doi: 10.1159/ 000329188.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2019 Issue 1
Most read in this issue
- Comparison of the benefits of FGM and CGM for different clinical scenarios in patients with type 1 diabetes mellitus
- The role of nebivolol in the treatment of cardiovascular diseases
- The most common causes of hospitalisation and death in patients with diabetes – results of the National Diabetology Registry
- Screening of asymptomatic carotid atherosclerosis in diabetic patients and its association with ankle-brachial index